Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
HYB New America High Income Fund
ACV Virtus Diversified Income & Convertible Fund
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
CCBC Chino Commercial Bancorp
INGR Ingredion Inc
PROF Profound Medical Corp

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.

Closing Price
Day's Change
0.50 (0.80%)
B/A Size
Day's High
Day's Low

10-day average volume:

Lowe's stock falls as profit rises above expectations but sales fell a bit shy as cold weather hurt

6:18 am ET May 18, 2022 (MarketWatch)

Share of Lowe's Cos. (LOW) fell 1.1% in premarket trading Wednesday, after the home improvement retailer reported a fiscal first-quarter profit that rose above expectations but total and same-store sales that fell a bit shy, hurt by unseasonably cold temperatures in April. Net income for the quarter to April 29 rose to $2.33 billion, or $3.51 a share, from $2.32 billion, or $3.21 a share, in the year-ago period. The FactSet consensus for earnings per share was $3.22. Sales declined 3.1% to $23.66 billion, below the FactSet consensus of $23.77 billion. Same-store sales fell 4.0%, compared with the FactSet consensus of a 2.5% decline, while U.S. same-stores sales decreased 3.8% to beat expectations of down 4.2%. "Because 75% of our customer base is DIY [do-it-yourself], our Q1 sales were disproportionately impacted by the cooler spring temperatures," said Chief Executive Marvin Ellison. "Now that spring has finally arrived, we are pleased with the improved sales trends we are seeing in May." The company affirmed its fiscal 2022 outlook for EPS of $13.10 to $13.60, for revenue of $97 billion to $99 billion and for share repurchases of about $12 billion. The stock has tumbled 24.9% year to date through Tuesday, while shares of rival Home Depot Inc. (HD) have dropped 27.5% and the S&P 500 has declined 14.2%.

-Tomi Kilgore


(END) Dow Jones Newswires

May 18, 2022 06:18 ET (10:18 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.